Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Eliza A Hawkes, FRACP,MDMBBS, Geoffrey Chong, MD, Charmaine Smith, Sze-Ting Lee, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, MBBS, Niles Elizabeth Nelson, BSc, MBBS, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, MBBS, MD FRACP, FRCPA, Colm Keane, MD, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Kate Manos, MBBS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136024

Published: 2020

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2648.

https://doi.org/10.1182/blood-2019-123899

Published: 2019

Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD

Blood (2019) 134 (Supplement_1): 2652.

https://doi.org/10.1182/blood-2019-125924

Published: 2019

Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): 333.

https://doi.org/10.1182/blood-2018-99-114243

Published: 2018

Journal Articles

Modelling Resistance to Emerging Epigenetic Therapies

Blood (2014) 124 (21): 3546.

https://doi.org/10.1182/blood.V124.21.3546.3546

Published: 2014

Journal Articles

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Chun Yew Fong, MBBS, George Grigoriadis, MBBS, PhD, BSc, Jay Hocking, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Hatem H. Salem, MD, FRACP, FRCPA, Andrew Spencer, MD, Andrew H Wei, MBBS, PhD

Blood (2011) 118 (21): 3631.

https://doi.org/10.1182/blood.V118.21.3631.3631

Published: 2011

NARROW

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Modelling Resistance to Emerging Epigenetic Therapies

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only